ESMO Congress 2026

The treatment of muscle-invasive bladder cancer (MIBC) has long taken radical cystectomy as the gold standard, but even with new anesthetic and surgical techniques the procedure carries high morbidity and mortality, and some patients are unfit for or refuse this major surgery; bladder preservation strategies were developed to reduce surgery-related morbidity and mortality while achieving similar oncologic control and better quality of life ^[6]. This established framework — surgery at the center with bladder preservation as a complement — is the reference point for understanding both the debate over systemic therapy and the intravesical-treatment exploration at this meeting.

The #ESMO26 posts present two parallel threads. First, @drenriquegrande asked: is this the end of platinum-based chemo + immunotherapy in bladder cancer, and what should be done with NIAGARA from now on? No efficacy figures were given in the post; echoing this thread is the presentation "Evolving Systemic Therapy in Bladder Cancer" by Robert Jones, MD, PhD (#MIBC / #UrothelialCancer). Second, Dr. Felix Guerrero presented an updated analysis of SunRISe-1, titled "Baseline and On-Treatment utDNA Molecular Residual Disease and Response to Gemcitabine Intravesical System", in the non-muscle-invasive bladder cancer (#NMIBC) setting; again, no figures were disclosed in the post.

Relative to the existing picture centered on surgery and bladder preservation ^[6], each thread moves one step forward. The systemic-therapy thread shifts the discussion from "surgery versus bladder preservation" to "whether platinum chemo plus immunotherapy remains the standard, and how treatment should be sequenced after NIAGARA"; Grande framed it as a question rather than a conclusion, indicating the issue remains open at the meeting, with the answer hinging on specific data not named in the post. The SunRISe-1 thread turns to intravesical therapy in NMIBC, examining whether baseline and on-treatment utDNA-MRD can dynamically identify responders to the gemcitabine intravesical system; the idea of using non-invasive urinary testing to guide function-preserving treatment echoes the logic of similar oncologic control and quality of life pursued by bladder preservation strategies ^[6], though the disease-stage settings differ and direct analogy is unwarranted.

The limitations must also be stated: all three posts are question-style or title-style communications, with no efficacy or safety figures, sample sizes, or follow-up details; the triggering data behind Grande's question are not specified in the post and remain to be confirmed; and the background literature contains no randomized controlled results on platinum chemo plus immunotherapy or utDNA-MRD for comparison. This note only maps the flow of conference information and does not constitute investment or clinical decision advice.